Abstract
Macrophages often function as control switches of the immune system, securing the balance between pro- and anti-inflammatory reactions. For this purpose and depending on the activating stimuli, macrophages can develop into different subsets: classically (M1) or alternatively (M2) activated macrophages, the characterization of which is a current topic of investigation. Accumulating evidence suggests that both populations, using their own specific mechanisms, may influence the behaviour of cancer cells, shape the tumor microenvironment and subverte anti-tumor immunity, thereby contributing to tumor growth and progression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Akagawa KS (2002) Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int J Hematol 76:27.
Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K (1995) Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75:552.
Akira S, Takeda K, Kaisho T (2001) Toll -like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675.
Alleva DG, Burger CJ, Elgert KD (1994) Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-f production: role of tumor-derived IL-10, TGF- , and prostaglandin E2. J Immunol 153:1674.
Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, Young HA, Zanovello P (2000) Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 165:6723.
Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY (2001) Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 7:3540.
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539.
Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62:7042.
Baron JA, Sandler RS (2000) Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51:511.
Baskic D, Acimovic L, Samardzic G, Vujanovic NL, Arsenijevic NN (2001) Blood monocytes and tumor-associated macrophages in human cancer: differences in activation levels. Neoplasma 48:169.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727.
Becker S, Daniel EG (1990) Antagonistic and additive effects of IL-4 and interferon-B on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 129:351.
Beissert S, Bergholz M, Waase I, Lepsien G, Schauer A, Pfizenmaier K, Krönke M (1989) Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci USA 86:5064.
Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23:201.
Berrebi D, Bruscoli S, Cohen N, Foussat A, Migliorati G, Bouchet-Delbos L, Maillot M-C, Portier A, Couderc J, Galanaud P, Peuchmaur M, Riccardi C, Emilie D (2003) Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 101:729.
Blesson S, Thiery J, Gaudin C, Stancou R, Kolb J-P, Moreau JL, Theze J, Mami-Chouaib F, Chouaib S (2002) Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 14:1169.
Bluestone JA, Lopez C (1983) Suppression of the immune response in tumor-bearing mice. III. Induction of functionally suppressive antigen-driven macrophages. Cancer Invest 1:5.
Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to IFN-9. Annu Rev Immunol 15:749.
Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2:907.
Bonder CS, Dickensheets HL, Finlay-Jones JJ, Donnelly RP, Hart PH (1998) Involvement of the IL-2 receptor gamma-chain in the control by IL-4 of human monocyte and macrophage proinflammatory mediator production. J Immunol 160:4048.
Bonecchi R, Sozzani S, Stine JT, Luini W, D’Amico G, Allavena P, Chantry D, Mantovani A (1998) Divergent effects of interleukin-4 and interferon-l on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses. Blood 92:2668.
Bonnotte B, Larmonier N, Favre N, Fromentin A, Moutet M, Martin M, Gurbuxani S, Solary E, Chauffert B, Martin F (2001) Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 167:5077.
Boon T, Coulie PG, Van den Eynde B (1997) Tumour antigens recognized by T cells. Immunol Today 18:267.
Boraschi D, Pasqualetto E, Ghezzi P, Salmona M, Bartalini M, Barbarulli G, Censini S, Soldateschi D, Tagliabue A (1983) Dissociation between macrophage tumoricidal capacity and suppressive activity: analysis with macrophage defective mouse strains. J Immunol 131:1707.
Brocker EB, Zwaldo G, Holzmann B, Macher E, Sorg C (1988) Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 41:562.
Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P (2000) Identification of a CD11b+/ Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 96:3838.
Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 170:270.
Burke F, Relf M, Negus R, Balkwill F (1996) A cytokine profile of normal and malignant ovary. Cytokine 8:578.
Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7:3.
Chang C-I, Liao JC, Kuo L (2001) Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 61:1100.
Chang M-DY, Pollard JW, Khalili H, Goyert SM, Diamond B (1993) Mouse placental macrophages have a decreased ability to present antigen. Proc Natl Acad Sci USA 90:462.
Chang ZL, Bonvini E, Varesio L, Holden HT, Herberman RB (1988) Differential in vitro modulation of suppressor and antitumor functions of mouse macrophages by lymphokines and/or endotoxin. Cell Immunol 114:282.
Cheung DL, Hart PH, Vitti GF, Whitty GA, Hamilton JA (1990) Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes. Immunology 71:70.
Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493.
Conrad DJ, Lu M (2000) Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am J Respir Cell Mol Biol 22:226.
Cordon-Cardo C, Prives C (1999) At the crossroads of inflammation and tumorigenesis. J Exp Med 190:1367.
Corraliza IM, Soler G, Eichmann K, Modolell M (1995) Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 206:667.
Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, Ricciardi_Castagnoli P, Rosen CA, Carter KC (1999) Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 94:411.
Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different! J Exp Med 193:F23.
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey G, Hanahan D (1999) Inflammatory mast-cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382.
Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP -9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481.
Davel LE, Jasnis MA, de la Torre E, Gotoh T, Diament M, Magenta G, Sacerdote de Lustig E, Sales ME (2002) Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages. FEBS Lett 532:216.
De Baetselier P, Namangala B, Noël W, Brys L, Pays E, Beschin A (2001) Alternative versus classical macrophage activation during experimental African trypanosomosis. Int J Parasitol 31:575.
De Marzo AM, Marchi VL, Epstein JI, Neson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985.
Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H (2003) Secretory Leukocyte Protease Inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 100:5778.
Di Carlo E, Forni G, Lollini PL, Colombo MP, Modesti A, Musiani P (2001) The intriguing role of polymorphonuclear neutrophils in anticancer reactions. Blood 97:339.
Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119.
DiNapoli MR, Calderon CL, Lopez DM (1996) The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J Exp Med 183:1323.
Djemadji-Oudjiel N, Goerdt S, Kodelja V, Schmuth M, Orfanos CE (1996) Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+, MS-1+/−, 25F9−) in psoriatic dermis. Arch Dermatol Res 288:757.
Duyndam MC, Hilhorst MC, Schluper HM, Verheul HM, van Diest PJ, Kraal G, Pinedo HM, Boven E (2002) Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 160:537.
Elgert KD, Alleva DG, Mullins DW (1998) Tumor -induced immune dysfunction: the macrophage connection. J Leukoc Biol 64:275.
Ernst P, Gold BD (2000) The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 54:615.
Evans R (1978) Macrophage requirement for growth of a murine fibrosarcoma. Br J Cancer 37:1086.
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-g, PGE2, and PAF. J Clin Invest 101:890.
Farias-Eisner R, Chaudhuri G, Aeberhard E, Fukuto JM (1996) The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistance/susceptibility. J Biol Chem 271:6144.
Fauve RM (1993) Macrophages and cancer: some aspects of the macrophage-cancer relationship. Res Immunol 144:265.
Fenton MJ, Buras JA, Donnelly RP (1992) IL -4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. J Immunol 149:1283.
Fidler IJ (1985) Macrophages and metastasis–a biological approach to cancer therapy. Cancer Res 45:4714.
Fidler IJ (1997) Molecular biology of cancer: invasion and metastasis. In: Devita VT et al. (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 135–152.
Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 42:496.
Flores Villanueva PO, Harris TS, Ricklan DE, Stadecker MJ (1994) Macrophages from schistosomal egg granulomas induce unresponsiveness in specific cloned Th1 lymphocytes in vitro and down-regulate schistosomal granulomatous disease in vivo. J Immunol 152:1847.
Fuchs EJ, Matzinger P (1996) Is cancer dangerous to the immune system? Semin Immunol 8:271.
Fujii T, Igarashi T, Kishimoto S (1987) Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice. J Natl Cancer Inst 78:509.
Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398.
Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Op Immunol 13:114.
Garcia Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 12:88.
Garofalo A, Chirivi R, Foglieni C, Pigott R, Mortarini R, Martin-Padura I, Anichini A, Gearing A, Sanchez-Madrid F, Dejana E (1995) Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastasis. Cancer Res 55:414.
Geldhof AB, Van Ginderachter JA, Liu YQ, Noël W, Raes G, De Baetselier P (2002) Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100:4049.
Geng YJ, Hansson GK (1992) Interferon -G inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest 89:1322.
Gifford GE, Lohmann-Matthes M-L (1986) The requirement for the continual presence of LPS for the production of TNF by thioglycolate induced peritoneal murine macrophages. Int J Cancer 38:135.
Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC (2001) Regulation of cutaneous malignancy by oo T cells. Science 294:605.
Goerdt S, Orfanos CE (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10:137.
Goerdt S, Bhardwaj R, Sorg C (1993) Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am J Pathol 142:1409.
Goerdt S, Walsh LJ, Murphy GF, Pober JS (1991) Identification of a novel high molecular weight protein preferentially expressed by sinusoidal endothelial cells in normal human tissues. J Cell Biol 113:1425.
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23.
Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E, Ruchatz AN, Emiliusen LM, Vile RG (2001) Macrophages orchestrate the immune response to tumor cell death. Cancer Res 61:7240.
Gratchev A, Guillot P, Hakiy N, Politz O, Orfanos CE, Schledzewski K, Goerdt S (2001) Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein tIG-H3. Scand J Immunol 53:386.
Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ (2000) Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407.
Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A (2000) The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 67:53.
Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144.
Hensley C, Spitzler S, McAlpine BE, Lynn M, Ansel JC, Solomon AR, Armstrong CA (1998) In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 7:335.
Hibbs Jr., JB, Vavrin Z, Taintor RR (1987) L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 138:550.
Holt PG, Schon-Hegard MA, Oliver J (1998) MHC class II antigen-bearing dendritic cells in pulmonary tissues of the rat. Regulation of antigen presentation activity by endogenous macrophage population. J Exp Med 167:262.
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375.
Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T (2001) Tumor rejection by disturbing tumor stroma-cell interactions. J Exp Med 194:1549.
Iellem A, Mariani M, Lang R, Recalde H, Panina_Bordignon P, Sinigaglia F, D_Ambrosio D (2001) Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+) CD25(+) regulatory T cells. J Exp Med 194:847.
Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184.
Kambayashi T, Alexander HR, Fong M, Strassmann G (1995) Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF- release via a mechanism involving IL-10. J Immunol 154:3383.
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an IFNO-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556.
Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999.
Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T-cell immune response. J Immunol 155:2240.
Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, Daemen T (2001) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61:7305.
Klostergaard J (1993) Macrophage tumoricidal mechanisms. Res Immunol 144:274.
Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM (1998) Immune suppression by recombinant interleukin (rIL)-12 involves interferon v induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 188:1603.
Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S (1997) Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 197:478.
Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S (1998) Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 i with a Th2-associated expression pattern. J Immunol 160:1411.
Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. J Int Med 248:171.
Kuroda E, Kito T, Yamashita U (2002) Reduced expression of STAT4 and IFN-S in macrophages from BALB/c mice. J Immunol 168:5477.
Kusmartsev SA, Li Y, Chan S-H (2000) Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 165:779.
Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE (1998) Association of tumour necrosisfactor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77:2246.
Leek RD, Landers RJ, Harris AL, Lewis CE (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79:991.
Lejeune FJ, Rüegg C, Liénard D (1998) Clinical applications of TNF-a in cancer. Curr Op Immunol 10:573.
Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony -stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727.
Liu YQ, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB (2003) NO-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 170:5064.
Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163:6251.
Loke P, MacDonald AS, Robb A, Maizels RM, Allen JE (2000) Alternatively activated macrophages induced by nematode infection inhibit proliferation via cell-to-cell contact. Eur J Immunol 30:2669.
Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M, Allen JE (2002) IL -4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol 3:7.
MacMicking J, Xie QW, Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323.
Maeda H, Shiraishi A (1996) TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 156:73.
Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A (1995) TGF-M enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 155:4926.
Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT (1995) Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 41:111.
Mantovani A (1999) The chemokine system: redundancy for robust outputs. Immunol Today 20:254.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13:265.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549.
Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM (2002) Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168:689.
McCawley LJ, Matrisian LM (2000) Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6:149.
Medot-Pirenne M, Heilman MJ, Saxena M, McDermott PE, Mills CD (1999) Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide. J Immunol 163:5877.
Medzhitov R, Janeway CA (2000) Innate immune recognition: mechanisms and pathways. Immunol Rev 173:89.
Meltzer MS (1981) Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J Immunol 127:179.
Metzger Z, Hoffeld JT, Oppenheim JJ (1980) Macrophage-mediated suppression. I. Evidence for participation of both hydrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation. J Immunol 124:983.
Mills CD (1991) Molecular basis of “suppressor” macrophages. Arginine metabolism via the nitric oxide synthetase pathway. J Immunol 146:2719.
Mills CD, Shearer J, Evans R, Caldwell MD (1992) Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 149:2709.
Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M -1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166.
Montaner LJ, da Silva RP, Sun J, Sutterwala S, Hollinshead M, Vaux D, Gordon S (1999) Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-c or IL-10. J Immunol 162:4606.
Mosser DM, Handman E (1992) Treatment of murine macrophages with interferon-M inhibits their ability to bind leishmania promastigotes. J Leukoc Biol 52:369.
Mueller C (2002) Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 105:1–8.
Mues B, Langer D, Zwadlo G, Sorg C (1989) Phenotypic characterization of macrophages in human term placenta. Immunology 67:303.
Munder M, Eichmann K, Modolell M (1998) Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 160:5347.
Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M (1999) Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163:3771.
Namangala B, De Baetselier P, Brijs L, Stijlemans B, Noël W, Pays E, Carrington M, Beschin A (2000) Attenuation of Trypanosoma brucei is associated with reduced immunosuppression and concomitant production of Th2 lymphokines. J Infect Dis 181:1110.
Namangala B, De Baetselier P, Noël W, Brys L, Beschin A (2001) Alternative versus classical macrophage activation during experimental African trypanosomosis. J Leukoc Biol 69:387.
Naylor MS, Stamp GW, Balkwill FR (1990) Investigation of cytokine gene expression in human colorectal cancer. Cancer Res 50:4436.
Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91:2194.
Nesbit M, Schaider H, Miller TH, Herlyn M (2001) Low -level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 166:6483.
Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459.
Nishioka Y, Sone S, Okubo A, Ogura T (1990) Suppression by interleukin-4 of activation of human blood monocytes to the tumoricidal state. Jpn J Cancer Res 81:936.
Nowicki A, Szenajch J, Ostrowska G, Wojtowicz A, Wojtowicz K, Kruszewski AA, Maruszynski M, Aukerman SL, Wiktor-Jedrzejczak W (1996) Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer 65:112.
O’Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 36:151.
Oehler JR, Hernerman RB, Campbell Jr., DA, Djeu JY (1977) Inhibition of rat mixed lymphocyte cultures by suppressor macrophages. Cell Immunol 29:238.
Okahara H, Yagita H, Miyake K, Okumura K (1994) Involvement of very late antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 54:3233.
Ono M, Torisu H, Fukushi J, Nisjie A, Kuwano M (1999) Biological implication of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 43:69.
Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T (1996) Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 s chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 93:13119.
Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW (1983) Macrophage activation to cytotoxicity by recombinant IFN-a. J Immunol 130:2011.
Parajuli P, Singh SM (1996) Alteration in IL-1 and arginase activity of tumor-associated macrophages: a role in the promotion of tumor growth. Cancer Lett 107:249.
Parhar RS, Lala PK (1988) Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J Leukoc Biol 44:474.
Park IC, Park MJ, Choe TB, Jang JJ, Hong SI, Lee SH (2000) TNF-alpha induces apoptosis mediated by AEBSF-sensitive serine protease(s) that may involve upstream caspase-3/CPP32 protease activation in a human gastric cancer cell line. Int J Oncol 16:1243.
Pegg AE (1988) Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48:759.
Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1.
Pelus LM, Bockman RS (1979) Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J Immunol 123:2118.
Peng L, Shu S, Krauss JC (1997) Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res 57:4849.
Polverini PJ, Leibovich J (1984) Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 51:635.
Raes G, Van Ginderachter J, Liu YQ, Brys L, Thielemans K, De Baetselier P, Geldhof A (1998) Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol Immunother 45:257.
Raes G, De Baetselier P, Noël W, Beschin A, Brombacher F, Hassanzadeh Gh G (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol 71:597.
Remels L, Fransen L, Huygen K, De Baetselier P (1990) Poly I:C activated macrophages are tumoricidal for TNF-T-resistant 3LL tumor cells. J Immunol 144:4477.
Rodriguez-Sosa M, Satoskar AR, Calderon R, Gomez-Garcia L, Saavedra R, Bojalil R, Terrazas LI (2002) Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR5 with low interleukin-12 production and Th2-biasing ability. Infect Immun 70:3656.
Ruggiero V, Johnson SE, Baglioni C (1987) Protection from tumor necrosis factor cytotoxicity by protease inhibitors. Cell Immunol 107:317.
Saio M, Radoja S, Marino M, Frey AB (2001) Tumor-infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol 167:5583.
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18.
Sallenave JM (2000) The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 1:87.
Sato M, Goto S, Kaneko R, Ito M, Sato S, Takeuchi S (1998) Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 18:3951.
Satoskar AR, Rodig S, Telford 3rd, SR, Satoskar AA, Ghosh SK, von Lichtenberg F, David JR (2000) IL -12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30:834.
Schebesch C, Kodelja V, Müller C, Hakij N, Bisson S, Orfanos CE, Goerdt S (1997) Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology 92:478.
Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D (2002) Tumor -associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947.
Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J (2002) Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277:24584.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFN o and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107.
Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC (2001) Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 167:2972.
Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-SB activation in tumor-associated macrophages. J Immunol 164:762.
Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumour surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661.
Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293.
Song E, Ouyang N, Horbelt M, Antus B, Wang M, Exton MS (2000) Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 204:19.
Sotomayor EM, DiNapoli MR, Calderon C, Colsky A, Fu YX, Lopez DM (1995) Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release. Int J Cancer 60:660.
Sotomayor EM, Borrello I, Levitsky HI (1996) Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog 7:433.
Standiford TJ, Kunkel SL, Liebler JM, Burdick MD, Gilbert AR, Strieter RM (1993) Gene expression of macrophage inflammatory protein-1 t from human blood monocytes and alveolar macrophages is inhibited by interleukin-4. Am J Respir Cell Mol Biol 9:192.
Starkey JR, Liggitt HD, Jones W, Hosick HL (1984) Influence of migratory blood cells on the attachment of tumor cells to vascular endothelium. Int J Cancer 34:535.
Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176:287.
Stevens SR, Shibaki A, Meunier L, Cooper KD (1995) Suppressor T cell-activating macrophages in ultraviolet-irradiated human skin induce a novel, TGF-n-dependent form of T cell activation characterized by deficient IL-2r - expression. J Immunol 155:5601.
Stuehr DJ, Nathan CF (1989) Nitric oxide, a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169:1543.
Suk K, Somers SD, Erickson KL (1993) Regulation of murine macrophage function by IL-4: IL-4 and IFN-S differentially regulate macrophage tumoricidal activation. Immunology 80:617.
Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C (1994) Macrophages and angiogenesis. J Leukoc Biol 55:410.
Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, Koch AE (1994) Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 37:221.
Takahashi A, Kono K, Ichihara F, Sugai H, Amemiya H, Iizuka H, Fujii H, Matsumoto Y (2003) Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer. Int J Cancer 104:393.
Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117.
Terrazas LI, Walsh KL, Piskorska D, McGuire E, Harn Jr., DA (2001) The schistosome oligosaccharide lacto-N-neotetraose expands Gr-1+ cells that secrete anti-inflammatory cytokines and inhibit proliferation of naïve CD4+ cells: a potential mechanism for immune polarization in helminth infections. J Immunol 167:5294.
Ting CC, Rodrigues D (1982) Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression. J Natl Cancer Inst 69–867.
Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M (2000) Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNF-a and IL-1a. Int J Cancer 85:182.
Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251.
Tsuchiya Y, Igarashi M, Suzuki R, Kumagai K (1988) Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J Immunol 141:699.
Tsunawaki S, Nathan CF (1986) Macrophage deactivation. Altered kinetic properties of superoxide-producing enzyme after exposure to tumor cell-conditioned medium. J Exp Med 164:1319.
Tsung K, Dolan JP, Tsung YL, Norton JA (2002) Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 62:5069.
Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA (2002) Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood 99:1465.
Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H (1986) Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83:5233.
van den Berg A, Visser L, Poppema S (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin’s lymphoma. Am J Pathol 154:1685.
Van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H (1996) Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184:1781.
Van Ginderachter JA, Liu YQ, Geldhof AB, Brys L, Thielemans K, De Baetselier P, Raes G (2000) B7–1, IFN-gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer 87:539.
Van Hal PT, Hopstaken-Broos JP, Wijkhuijs JM, Te Velde AA, Figdor CG, Hoogsteden HC (1992) Regulation of aminopeptidase-N (CD13) and FcV RIIb (CD23) expression by IL-4 depends on the stage of maturation of monocytes/macrophages. J Immunol 149:1395.
VandenDriessche T, Bakkus M, Toussaint-Demylle D, Thielemans K, Verschueren H, De Baetselier P (1994) Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens. Clin Exp Metastasis 12:73.
Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL (1992) Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 51:573.
Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB (1987) Transforming growth factor type s induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 84:5788.
Welch JS, Escoubet-Lozach L, Sykes DB, Liddiard K, Greaves DR, Glass CK (2002) Th2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism. J Biol Chem 277:42821.
Whiteside TL, Herberman RB (1995) The role of natural killer cells in immune surveillance of cancer. Curr Op Immunol 7:704.
Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA (2002) Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 21:881.
Wu G, Morris Jr., SM, (1998) Arginine metabolism: nitric oxide and beyond. Biochem J 336(Pt 1):1.
Zhang F, Lu W, Dong Z (2002) Tumor -infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by IFN-beta gene therapy in nude mice. Clin Cancer Res 8:2942.
Zhang Y, Khoo HE, Esuvaranathan K (1999) Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 161:977.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Van Ginderachter, J. et al. (2008). Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion. In: Kaiser, H.E., Nasir, A. (eds) Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response. Cancer Growth and Progression, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6729-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6729-7_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6728-0
Online ISBN: 978-1-4020-6729-7
eBook Packages: MedicineMedicine (R0)